David Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
David Yang has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Tobias S. Kohler
Mayo Clinic
3 shared publications - Joshua Savage
University of Birmingham 3 Cancer Research UK Clinical Trials Unit Birmingham, United Kingdom
2 shared publications - Landon Trost
Mayo Clinic, Rochester, USA
2 shared publications Matthew Ziegelmann
Department of Urology , Mayo Clinic, Rochester, MN 55905, United States
2 shared publications- Sevann Helo
Department of Urology, Mayo Clinic, Rochester, MN, USA
2 shared publications - Abrar Mian
Mayo Clinic Rochester, Department of Urology, Rochester, MN, USA
1 shared publication
Latest Publications
- Open Access
- 11 January 2023
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 20 (1) , 107-112
Timing and causative organisms associated with modern inflatable penile prosthesis infection: an institutional retrospective
The advent of antibiotic-coated devices has reduced the rate of inflatable penile prosthesis (IPP) infections; however, this may have altered microbial profiles when infections do occur. To describe the timing and causative organisms behind infection of infection retardant–coated IPPs in the context of our institution’s perioperative antimicrobial protocols. We retrospectively reviewed all patients undergoing IPP placement at our institution from January 2014 to January 2022. In all patients, perioperative antibiotic administration was congruent with American Urological Association guidelines. Boston Scientific devices are impregnated with InhibiZone (rifampin and minocycline), and all Coloplast devices were soaked in rifampin and gentamicin. Intraoperative irrigation was performed with betadine 5% irrigation prior to November 2016 and with vancomycin-gentamicin solution afterward. Cases involving prosthesis infection were identified, and variables were extracted from the medical record. Descriptive and comparative statistics were tabulated to identify clinical characteristics, including patient comorbidities, prophylaxis regimen, symptom onset, and intraoperative culture result. We previously reported an increased infection risk with Betadine irrigation and stratified results accordingly. The primary outcome was time to infectious symptoms, while the secondary outcome was description of device cultures at the time of explantation. A total of 1071 patients underwent IPP placement over 8 years with an overall infection rate of 2.6% (28/1071). After discontinuation of Betadine, the overall infection rate was significantly lower at 0.9% (8/919) with a relative risk of 16.9 with Betadine (P < .0001). Primary procedures represented 46.4% (13/28). Of 28 patients with infection, only 1 had no identified risk factors; the remainder included Betadine at 71% (20/28), revision/salvage procedure at 53.6% (15/28), and diabetes at 50% (14/28). Median time to symptoms was 36 days (IQR, 26-52); almost 30% of patients had systemic symptoms. Organisms with high virulence, or ability to cause disease, were found in 90.5% (19/21) of positive cultures. Our study revealed a median time to symptoms of just over 1 month. Risk factors for infection were Betadine 5% irrigation, diabetes, and revision/salvage cases. Over 90% causative organisms were virulent, demonstrating a microbial profile trend since antibiotic coating development. The large prospectively maintained database is a strength along with the ability to follow specific changes in perioperative protocols. The retrospective nature of the study is a limitation as well as the low infection rate, which limits certain subanalyses from being performed. IPP infections present in a delayed manner despite the rising virulence of infecting organisms. These findings highlight areas for improvement in perioperative protocols in the contemporary prosthetics era.
- 11 January 2023
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 20 (1) , 107-112
Open AccessTiming and causative organisms associated with modern inflatable penile prosthesis infection: an institutional retrospective
The advent of antibiotic-coated devices has reduced the rate of inflatable penile prosthesis (IPP) infections; however, this may have altered microbial profiles when infections do occur. To describe the timing and causative organisms behind infection of infection retardant–coated IPPs in the context of our institution’s perioperative antimicrobial protocols. We retrospectively reviewed all patients undergoing IPP placement at our institution from January 2014 to January 2022. In all patients, perioperative antibiotic administration was congruent with American Urological Association guidelines. Boston Scientific devices are impregnated with InhibiZone (rifampin and minocycline), and all Coloplast devices were soaked in rifampin and gentamicin. Intraoperative irrigation was performed with betadine 5% irrigation prior to November 2016 and with vancomycin-gentamicin solution afterward. Cases involving prosthesis infection were identified, and variables were extracted from the medical record. Descriptive and comparative statistics were tabulated to identify clinical characteristics, including patient comorbidities, prophylaxis regimen, symptom onset, and intraoperative culture result. We previously reported an increased infection risk with Betadine irrigation and stratified results accordingly. The primary outcome was time to infectious symptoms, while the secondary outcome was description of device cultures at the time of explantation. A total of 1071 patients underwent IPP placement over 8 years with an overall infection rate of 2.6% (28/1071). After discontinuation of Betadine, the overall infection rate was significantly lower at 0.9% (8/919) with a relative risk of 16.9 with Betadine (P < .0001). Primary procedures represented 46.4% (13/28). Of 28 patients with infection, only 1 had no identified risk factors; the remainder included Betadine at 71% (20/28), revision/salvage procedure at 53.6% (15/28), and diabetes at 50% (14/28). Median time to symptoms was 36 days (IQR, 26-52); almost 30% of patients had systemic symptoms. Organisms with high virulence, or ability to cause disease, were found in 90.5% (19/21) of positive cultures. Our study revealed a median time to symptoms of just over 1 month. Risk factors for infection were Betadine 5% irrigation, diabetes, and revision/salvage cases. Over 90% causative organisms were virulent, demonstrating a microbial profile trend since antibiotic coating development. The large prospectively maintained database is a strength along with the ability to follow specific changes in perioperative protocols. The retrospective nature of the study is a limitation as well as the low infection rate, which limits certain subanalyses from being performed. IPP infections present in a delayed manner despite the rising virulence of infecting organisms. These findings highlight areas for improvement in perioperative protocols in the contemporary prosthetics era.
- 1 March 2021
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 18 (Supplement) , S37
068 Use of RestoreX Penile Traction Therapy for Treatment of Penile Length Loss in Diabetic Men
Penile length loss is a common complaint among men with diabetes mellitus (DM). Although robust epidemiological studies are lacking, limited data suggest reductions in all penile dimensions among diabetic men, including a mean 1 cm loss compared to men without DM. Penile traction therapy (PTT) is one treatment often recommended to help restore lost penile length. Recently, a novel PTT device, RestoreX, was developed in cooperation with Mayo Clinic Ventures and demonstrated significant length improvements with 30 minutes daily use.
- 1 March 2021
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 18 (Supplement) , S37
068 Use of RestoreX Penile Traction Therapy for Treatment of Penile Length Loss in Diabetic Men
Penile length loss is a common complaint among men with diabetes mellitus (DM). Although robust epidemiological studies are lacking, limited data suggest reductions in all penile dimensions among diabetic men, including a mean 1 cm loss compared to men without DM. Penile traction therapy (PTT) is one treatment often recommended to help restore lost penile length. Recently, a novel PTT device, RestoreX, was developed in cooperation with Mayo Clinic Ventures and demonstrated significant length improvements with 30 minutes daily use.
- 14 December 2020
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 34 (1) , 100-107
Conservative management of suspected fractures in men undergoing collagenase clostridium histolyticum for Peyronie’s Disease is not associated with worsening of erectile function
The optimal management of suspected penile fractures post collagenase clostridium histolyticum (CCH) remains indeterminate, with some advocating for observation and others surgical repair. To address this issue, the current study sent surveys to 158 men with Peyronie’s Disease (PD) who completed four CCH injection series. The survey included the Erectile Function Domain from the International Index of Erectile Function (IIEF-EFD) and questions regarding potential symptoms of corporal rupture (hematoma, popping, and detumescence). Men were categorized as having a suspected fracture (SF+) if they reported a popping sensation or rapid detumescence. All SF(+) men were managed conservatively without surgical intervention. Results were compared statistically against baseline IIEF-EFD values and between SF(+) and SF(−) groups. The key study objective was to determine whether erectile function was negatively impacted by conservative management of suspected fractures. Of the 53 returned surveys, 45 had complete data for review. The sample was statistically representative of the broader cohort of 158 men, except being older (60.0 vs 57.1 [SD 6.0 vs 9.0], p = 0.01) with shorter durations of PD (median 9 [IQR 5, 19] mo vs 13 [IQR 8, 24], p = 0.01). Overall, 7/45 (16%) of men were defined as SF(+), with all fractures occurring within 6 weeks of CCH administration. No demographic or pathophysiologic characteristics predicted SF(+). Importantly, SF(+) men did not experience worsened erectile function compared to SF(−), with a median IIEF-EFD change of +2 vs +1, p = 0.16, respectively. Curvatures were improved to a greater degree among SF(+) men (primary: median −30 [IQR −20, −32.5] vs −15 [−5, −26], p = 0.04; composite: −35 [−25, −40] vs −25 [−7, −30], p = 0.15). We concluded that suspected penile fractures in PD men undergoing CCH may be reasonably managed without surgical intervention and portend greater improvements in curvature correction.
- 14 December 2020
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 34 (1) , 100-107
Conservative management of suspected fractures in men undergoing collagenase clostridium histolyticum for Peyronie’s Disease is not associated with worsening of erectile function
The optimal management of suspected penile fractures post collagenase clostridium histolyticum (CCH) remains indeterminate, with some advocating for observation and others surgical repair. To address this issue, the current study sent surveys to 158 men with Peyronie’s Disease (PD) who completed four CCH injection series. The survey included the Erectile Function Domain from the International Index of Erectile Function (IIEF-EFD) and questions regarding potential symptoms of corporal rupture (hematoma, popping, and detumescence). Men were categorized as having a suspected fracture (SF+) if they reported a popping sensation or rapid detumescence. All SF(+) men were managed conservatively without surgical intervention. Results were compared statistically against baseline IIEF-EFD values and between SF(+) and SF(−) groups. The key study objective was to determine whether erectile function was negatively impacted by conservative management of suspected fractures. Of the 53 returned surveys, 45 had complete data for review. The sample was statistically representative of the broader cohort of 158 men, except being older (60.0 vs 57.1 [SD 6.0 vs 9.0], p = 0.01) with shorter durations of PD (median 9 [IQR 5, 19] mo vs 13 [IQR 8, 24], p = 0.01). Overall, 7/45 (16%) of men were defined as SF(+), with all fractures occurring within 6 weeks of CCH administration. No demographic or pathophysiologic characteristics predicted SF(+). Importantly, SF(+) men did not experience worsened erectile function compared to SF(−), with a median IIEF-EFD change of +2 vs +1, p = 0.16, respectively. Curvatures were improved to a greater degree among SF(+) men (primary: median −30 [IQR −20, −32.5] vs −15 [−5, −26], p = 0.04; composite: −35 [−25, −40] vs −25 [−7, −30], p = 0.15). We concluded that suspected penile fractures in PD men undergoing CCH may be reasonably managed without surgical intervention and portend greater improvements in curvature correction.
- Open Access
- 8 December 2020
- Published by Oxford University Press (OUP) in Sexual Medicine
- Vol. 9 (1) , 100282
Vascular Necrosis of the Upper Extremity After Self-Treatment for Peyronie's Disease
Peyronie's disease (PD) is associated with significant psychosocial distress, including anxiety, depression, and negative effects on interpersonal relationships. We report outcomes in a patient who researched an enzymatic supplement intended for oral administration for treatment of PD and subsequently self-injected it intravascularly. The enzyme, a combination of serrapeptase and nattokinase, resulted in vascular necrosis of the upper extremity. Despite attempts to salvage the limb, he ultimately required transhumeral amputation. Although extreme, this case illustrates the potential risks of non–Food and Drug Administration–approved therapies, the significant psychosocial impact that PD can have on patients' emotional well-being, and the extent to which some may go to seek treatment. Yang D, Savage J, Kohler T, et al. Vascular Necrosis of the Upper Extremity After Self-Treatment for Peyronie's Disease. Sex Med 2021;9:100282.
- 8 December 2020
- Published by Oxford University Press (OUP) in Sexual Medicine
- Vol. 9 (1) , 100282
Open AccessVascular Necrosis of the Upper Extremity After Self-Treatment for Peyronie's Disease
Peyronie's disease (PD) is associated with significant psychosocial distress, including anxiety, depression, and negative effects on interpersonal relationships. We report outcomes in a patient who researched an enzymatic supplement intended for oral administration for treatment of PD and subsequently self-injected it intravascularly. The enzyme, a combination of serrapeptase and nattokinase, resulted in vascular necrosis of the upper extremity. Despite attempts to salvage the limb, he ultimately required transhumeral amputation. Although extreme, this case illustrates the potential risks of non–Food and Drug Administration–approved therapies, the significant psychosocial impact that PD can have on patients' emotional well-being, and the extent to which some may go to seek treatment. Yang D, Savage J, Kohler T, et al. Vascular Necrosis of the Upper Extremity After Self-Treatment for Peyronie's Disease. Sex Med 2021;9:100282.
- 1 December 2019
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 37 (12) , 886-892
Incidence and risk factors for peritoneal carcinomatosis following open radical cystectomy
- 1 December 2019
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 37 (12) , 886-892
Incidence and risk factors for peritoneal carcinomatosis following open radical cystectomy